Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses

The Lancet Psychiatry

Volumn 2, Issue 5, 2015, Pages 452-464

  Henderson, David C ^a,b   Vincenzi, Brenda ^a   Andrea, Nicolas V ^a   Ulloa, Melissa ^a   Copeland, Paul M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DYSREGULATION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LIFESTYLE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; REVIEW; SCHIZOPHRENIA; SMOKING; WEIGHT GAIN; CARDIOVASCULAR DISEASES; MENTAL DISEASE; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

CARDIOVASCULAR DISEASES; HUMANS; MENTAL DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84933555992     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00115-7     Document Type: Review

References (137)

1. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10:52-77.
2. Bushe CJ, Taylor M, Haukka J Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010, 24(suppl):17-25.
3. Laursen TM, Nordentoft M, Mortensen PB Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014, 10:425-448.
4. Saha S, Chant D, McGrath J A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007, 64:1123-1131.
5. Colton CW, Manderscheid RW Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:A42.
6. Laursen TM, Munk-Olsen T, Vestergaard M Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012, 25:83-88.
7. Brown S, Inskip H, Barraclough B Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217.
8. Osby U, Correia N, Brandt L, Ekbom A, Sparén P Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000, 45:21-28.
9. Holt RI, Mitchell AJ Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 2015, 11:79-89.
10. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull 2011, 37:832-838.
11. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005, 80:45-53.
12. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
13. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
14. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004, 49:753-760.
15. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005, 66:1116-1121.
16. De Hert M, Schreurs V, Vancampfort D, van Winkel R Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8:15-22.
17. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013, 47:197-207.
18. Bly MJ, Taylor SF, Dalack G, et al. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord 2014, 16:277-288.
19. Hennekens CH, Hennekens AR, Hollar D, Casey DE Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005, 150:1115-1121.
20. Bobes J, Arango C, Garcia-Garcia M, Rejas J Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010, 119:101-109.
21. Kilbourne AM, Morden NE, Austin K, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry 2009, 31:555-563.
22. Vancampfort D, Probst M, Scheewe T, et al. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia. Psychiatry Res 2013, 207:25-32.
23. Bergman BC, Perreault L, Hunerdosse D, et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 2012, 61:3156-3166.
24. Cho NH, Chan JC, Jang HC, Lim S, Kim HL, Choi SH Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study. Clin Endocrinol (Oxf) 2009, 71:679-685.
25. Manu P, Tsang J, Napolitano BA, Lesser ML, Correll CU Predictors of insulin resistance in the obese with metabolic syndrome. Eur J Intern Med 2010, 21:409-413.
26. Hasnain M, Vieweg WV Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle?. Acta Psychiatr Scand 2011, 123:409-410.
27. Libby P, Tabas I, Fredman G, Fisher EA Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014, 114:1867-1879.
28. Maury E, Brichard SM Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010, 314:1-16.
29. Miller BJ, Culpepper N, Rapaport MH C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 2014, 7:223-230.
30. Henderson DC, Copeland PM, Nguyen DD, et al. Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta Psychiatr Scand 2006, 113:121-125.
31. Fan X, Goff DC, Henderson DC Inflammation and schizophrenia. Expert Rev Neurother 2007, 7:789-796.
32. Miller BJ, Culpepper N, Rapaport MH, Buckley P Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:92-100.
33. Drexhage RC, Weigelt K, van Beveren N, et al. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol 2011, 101:169-201.
34. Bergink V, Gibney SM, Drexhage HA Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 2014, 75:324-331.
35. Giovanoli S, Engler H, Engler A, et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 2013, 339:1095-1099.
36. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
37. Naudin J, Capo C, Giusano B, Mège JL, Azorin JM A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr Res 1997, 26:227-233.
38. Monteleone P, Fabrazzo M, Tortorella A, Maj M Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 1997, 71:11-17.
39. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007, 149:267-271.
40. Deng C Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013, 42:545-563.
41. Hotamisligil GS Inflammation and metabolic disorders. Nature 2006, 444:860-867.
42. Shoelson SE, Lee J, Goldfine AB Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
43. Fan X, Liu EY, Freudenreich O, et al. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 2010, 118:211-217.
44. Yao JK, Keshavan MS Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15:2011-2035.
45. Walss-Bass C, Weintraub ST, Hatch J, Mintz J, Chaudhuri AR Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol 2008, 11:1097-1104.
46. Miljevic C, Nikolic M, Nikolic-Kokic A, et al. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:303-307.
47. Arai M, Yuzawa H, Nohara I, et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry 2010, 67:589-597.
48. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
49. Bak M, Fransen A, Janssen J, van Os J, Drukker M Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014, 9:e94112.
50. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999, 60:215-220.
51. Fernø J, Varela L, Skrede S, et al. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One 2011, 6:e20571.
52. Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN Obesity, adipokines and neuroinflammation. Neuropharmacology 2015, published online online Jan 10. 10.1016/j.neuropharm.2014.12.023.
53. Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006, 20:75-79.
54. Sentissi O, Epelbaum J, Olié JP, Poirier MF Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008, 34:1189-1199.
55. Sugai T, Suzuki Y, Fukui N, et al. Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. J Clin Psychopharmacol 2012, 32:390-393.
56. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005, 30:184-191.
57. De Ambrogi M, Volpe S, Tamanini C Ghrelin: central and peripheral effects of a novel peptydil hormone. Med Sci Monit 2003, 9:RA217-RA224.
58. Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 2004, 172:230-232.
59. Correll CU, Malhotra AK Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004, 174:477-489.
60. Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005, 30:106-110.
61. Russell JM, Mackell JA Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001, 15:537-551.
62. Fountaine RJ, Taylor AE, Mancuso JP, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 2010, 18:1646-1651.
63. Lu ML, Wang TN, Lin TY, et al. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2015, 58:47-50.
64. Ikegami M, Ikeda H, Ishikawa Y, et al. Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus. Eur J Pharmacol 2013, 718:376-382.
65. Ridker PM LDL cholesterol: controversies and future therapeutic directions. Lancet 2014, 384:607-617.
66. Nordestgaard BG, Varbo A Triglycerides and cardiovascular disease. Lancet 2014, 384:626-635.
67. Saydah S, Bullard KM, Cheng Y, et al. Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999-2010. Obesity (Silver Spring) 2014, 22:1888-1895.
68. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association, the American Psychiatric Associationthe American Psychiatric Association, the American Association of Clinical Endocrinologiststhe American Association of Clinical Endocrinologists, the North American Association for the Study of Obesitythe North American Association for the Study of Obesity.
69. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000, 157:975-981.
70. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002, 59:1021-1026.
71. Hasnain M, Vieweg WV, Hollett B Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012, 124:154-167.
72. Subramanian S, Chait A Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta 2012, 1821:819-825.
73. Meyer JM Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001, 62(suppl 27):27-34.
74. Goncalves P, Araujo JR, Martel F Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol 2015, 25:1-16.
75. Meyer JM, Koro CE The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004, 70:1-17.
76. Vestri HS, Maianu L, Moellering DR, Garvey WT Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32:765-772.
77. Minet-Ringuet J, Even PC, Valet P, et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 2007, 12:562-571.
78. Shimano H SREBPs: physiology and pathophysiology of the SREBP family. FEBS J 2009, 276:616-621.
79. Horton JD, Goldstein JL, Brown MS SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125-1131.
80. Lauressergues E, Staels B, Valeille K, et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:427-439.
81. Oh KJ, Park J, Lee SY, et al. Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am J Physiol Endocrinol Metab 2011, 300:E624-E632.
82. Lauressergues E, Martin F, Helleboid A, et al. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn Schmiedebergs Arch Pharmacol 2011, 383:423-436.
83. Canfrán-Duque A, Casado ME, Pastor O, et al. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 2013, 54:310-324.
84. Kristiana I, Sharpe LJ, Catts VS, Lutze-Mann LH, Brown AJ Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J 2010, 10:396-407.
85. Liou YJ, Tsai SJ, Wang YC, Bai YM, Hong CJ Genetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. J Clin Psychopharmacol 2013, 33:313-318.
86. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005, 62:19-28.
87. Reynolds GP Metabolic syndrome and schizophrenia. Br J Psychiatry 2006, 188:86-87.
88. Koller EA, Cross JT, Doraiswamy PM, Schneider BS Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003, 23:735-744.
89. Koller EA, Weber J, Doraiswamy PM, Schneider BS A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004, 65:857-863.
90. Kohen I, Gampel M, Reddy L, Manu P Rapidly developing hyperglycemia during treatment with olanzapine. Ann Pharmacother 2008, 42:588-591.
91. Makhzoumi ZH, McLean LP, Lee JH, Ibe AI Diabetic ketoacidosis associated with aripiprazole. Pharmacotherapy 2008, 28:1198-1202.
92. Reynolds GP, Kirk SL Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther 2010, 125:169-179.
93. Henderson DC Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002, 16:77-89.
94. Bergman RN, Ader M Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005, 66:504-514.
95. Newcomer JW Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(suppl 1):1-93.
96. Saltiel AR, Kahn CR Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
97. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuropsychopharmacol Biol Psychiatry 1999, 23:69-80.
98. Dwyer DS, Donohoe D Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003, 75:255-260.
99. Melkersson K, Jansson E Effects of the atypical antipsychotic clozapine on insulin release in vitro. Neuroendocrinol Lett 2007, 28:854-860.
100. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006, 67:789-797.
101. Weston-Green K, Huang XF, Lian J, Deng C Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol 2012, 22:364-373.
102. Hardy TA, Henry RR, Forrester TD, et al. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes Obes Metab 2011, 13:726-735.
103. Sato Y, Yasui-Furukori N, Furukori H, Saito M, Nakagami T, Kaneko S A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients. Exp Clin Psychopharmacol 2010, 18:445-450.
104. Boyda HN, Ramos-Miguel A, Procyshyn RM, et al. Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug. Int J Neuropsychopharmacol 2014, 17:77-90.
105. Mondelli V, Anacker C, Vernon AC, et al. Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Transl Psychiatry 2013, 3:e208.
106. Girault EM, Guigas B, Alkemade A, et al. Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects. Naunyn Schmiedebergs Arch Pharmacol 2014, 387:185-195.
107. Baig MR, Navaira E, Escamilla MA, Raventos H, Walss-Bass C Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations. J Psychiatr Pract 2010, 16:325-333.
108. Deng C, Weston-Green K, Huang XF The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1-4.
109. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
110. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009, 29:165-169.
111. Deng C, Chen J, Hu C, Huang XF What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?. J Clin Psychopharmacol 2010, 30:480-481.
112. Roerig JL, Steffen KJ, Mitchell JE, Crosby RD, Gosnell BA An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects. Biol Psychiatry 2009, 65:607-613.
113. Correll CU, Lencz T, Malhotra AK Antipsychotic drugs and obesity. Trends Mol Med 2011, 17:97-107.
114. Ferraioli A, Shirley KL, David P The role of atypical antipsychotics in glucose/insulin dysregulation and the evolving role of the psychiatrist in a new era of drug treatment options. CNS Spectr 2004, 9:849-861.
115. Deng C Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013, 42:545-563.
116. Reynolds GP, Zhang Z, Zhang X Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003, 160:677-679.
117. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006, 113:142-147.
118. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005, 133B:97-100.
119. Hong CJ, Lin CH, Yu YW, Yang KH, Tsai SJ Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001, 11:265-268.
120. Theisen FM, Hinney A, Brömel T, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004, 14:139-142.
121. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005, 134B:76-78.
122. Nurjono M, Tay YH, Lee J The relationship between serum brain-derived neurotrophic factor (BDNF) and cardiometabolic indices in schizophrenia. Schizophr Res 2014, 157:244-248. 10.1016/j.schres.2014.05.024.
123. Yoon S, Noh JS, Choi SY, Baik JH Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice. Biochem Biophys Res Commun 2010, 393:235-241.
124. Reinholz J, Skopp O, Breitenstein C, Bohr I, Winterhoff H, Knecht S Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations. Nutr Metab (Lond) 2008, 5:35.
125. Yu W, De Hert M, Moons T, Claes SJ, Correll CU, van Winkel R CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2013, 33:186-192.
126. Girault EM, Toonen PW, Eggels L, et al. Olanzapine-induced changes in glucose metabolism are independent of the melanin-concentrating hormone system. Psychoneuroendocrinology 2013, 38:2640-2646.
127. Peerbooms OLJ, van Os J, Drukker M, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability?. Brain Behav Immun 2011, 25:1530-1543. the MTHFR in Psychiatry Group.
128. Devlin AM, Ngai YF, Ronsley R, Panagiotopoulos C Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Transl Psychiatry 2012, 2:e71.
129. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002, 288:2023-2031. the MTHFR Studies Collaboration Group.
130. Shu S, Liu H, Wang M, Su D, Yao L, Wang G Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic β cells. J Endocrinol Invest 2014, 37:667-673.
131. Wu X, Huang Z, Wu R, et al. The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls. Schizophr Res 2013, 150:157-162.
132. Yan H, Chen JD, Zheng XY Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia. Psychopharmacology (Berl) 2013, 229:1-7.
133. Palik E, Birkás KD, Faludi G, Karádi I, Cseh K Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005, 68(suppl 1):S60-S64.
134. Fargali S, Sadahiro M, Jiang C, et al. Role of neurotrophins in the development and function of neural circuits that regulate energy homeostasis. J Mol Neurosci 2012, 48:654-659.
135. Henderson DC Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005, 66(suppl 6):11-20.
136. Sárvári AK, Veréb Z, Uray IP, Fésüs L, Balajthy Z Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. Biochem Biophys Res Commun 2014, 450:1383-1389.
137. Baig MR, Navaira E, Escamilla MA, Raventos H, Walss-Bass C Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations. J Psychiatr Pract 2010, 16:325-333.